Archiv
Archiv anzeigen:
bis


Bevacizumab Maintenance Therapy for Colorectal Cancer

David H. Ilson, MD, PhD reviewing Aparicio T et al. J Clin Oncol 2018 Mar 1

Outcomes were not improved with bevacizumab maintenance monotherapy versus observation.


Neutrophil Extracellular Traps Predict Venous Thromboembolism

David Green, MD, PhD reviewing Mauracher LM et al. J Thromb Haemost 2018 Mar

Histone H3, a NETS biomarker, is an independent predictor of VTE in cancer patients.


Postoperative Carcinoembryonic Antigen Levels Are Prognostic in Colon Cancer

David H. Ilson, MD, PhD reviewing Konishi T et al. JAMA Oncol 2018 Mar 1

Relapse-free survival was inferior in stage III patients with persistent postoperative CEA elevation.


Gene Therapy for β-Thalassemia

David Green, MD, PhD reviewing Thompson AA et al. N Engl J Med 2018 Apr 19, Biffi A. N Engl J Med 2018 Apr 19

The need for long-term red cell transfusions was reduced without serious adverse events.


Managing Alopecia Caused by Adjuvant Endocrine Therapy for Breast Cancer

Andrew M. Kaunitz, MD reviewing Freites-Martinez A et al. JAMA Dermatol 2018 Apr 11, Trüeb RM. JAMA Dermatol 2018 Apr 11

Topical minoxidil was effective in patients with hair loss caused by tamoxifen or aromatase inhibitors.


The Pathogenesis of Expanded DLBCL Subsets

Michael E. Williams, MD, ScM reviewing Schmitz R et al. N Engl J Med 2018 Apr 12

Multiplatform molecular analysis revealed clinically relevant diffuse large B-cell lymphoma subtypes that may inform future therapeutic approaches.


Autologous Stem Cell Transplantation for POEMS Syndrome

David Green, MD, PhD reviewing Ohwada C et al. Blood 2018 Mar 29

Five-year progression-free survival was 63% and overall survival was 90%.


Are Deep Remissions Prognostic in Acute Myeloid Leukemia?

Michael E. Williams, MD, ScM reviewing Jongen-Lavrencic M et al. N Engl J Med 2018 Mar 29, Steensma DP and Ebert BL. N Engl J Med 2018 Mar 29

Achievement of undetectable residual disease was associated with lower relapse rate and improved survival after induction therapy.


Shorter Duration Adjuvant Therapy for Stage III Colon Cancer

David H. Ilson, MD, PhD reviewing Grothey A et al. N Engl J Med 2018 Mar 29, Schilsky RL. N Engl J Med 2018 Mar 29

Three months of capecitabine and oxaliplatin therapy was noninferior to 6 months of therapy in patients with lower-risk disease.


Combining Targeted Therapies for Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Tam CS et al. N Engl J Med 2018 Mar 29

Venetoclax plus ibrutinib provided high response rates in relapsed or refractory disease.


Archiv
Seite von 67
Editorial Member Board Empfehlungen

PD Dr. med. Katja Zirlik

Hämatologie und internistische Onkologie
Tumorzentrum ZeTuP Chur

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Beim nicht kleinzelligen Lungenkarzinom (NSCLC) ist die Immuntherapie bereits in allen Therapielinien zugelassen. Die immunhistochemische Bestimmung der PD-L1-Expression auf den Tumorzellen ist derzeit der am besten validierte prädiktive Biomarker für die Therapie mit Checkpoint-Inhibitoren. Die vorliegende Studie untersuchte bei 848 Patienten mit NSCLC, ob die Mutationslast («tumor mutational burden», TMB), mittels «next-generation sequencing» (NGS) bestimmt, einen weiteren Marker darstellt, der die Wirksamkeit der Immuntherapie vorhersagen kann. Eine höhere Mutationslast war assoziiert mit einer Verbesserung im Hinblick auf die Ansprechrate sowie die Ansprechdauer. NSCLC-Patienten mit einer hohen Mutationslast profitieren demnach mehr von einer Immuntherapie.

Kommentar weiterlesen

First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.


Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.